Symbols

SBIO

ALPS Medical Breakthroughs ETF·ARCA

--(--)

Key Stats

Assets Under Management

138.46MUSD

Fund Flows (1Y)

-5.74MUSD

Dividend Yield

2.29%

Discount/Premium to NAV

-0.06%

Shares Outstanding

2.70M

Expense Ratio

0.50%

About ALPS Medical Breakthroughs ETF

Issuer

ALPS Advisors, Inc.

Brand

ALPS

Home Page

https://www.alpsfunds.com/exchange-traded-funds/sbio

Inception Date

Dec 30, 2014

Structure

Open-Ended Fund

Index Tracked

S-Network Medical Breakthroughs Index

Management Style

Passive

Dividend Treatment

Distributes

Distribution Tax Treatment

Qualified dividends

Income Tax Type

Capital Gains

Max ST Capital Gains Rate

39.60%

Max LT Capital Gains Rate

20.00%

Primary Advisor

ALPS Advisors, Inc.

Distributor

ALPS Portfolio Solutions Distributor, Inc.

SBIO invests in a concentrated portfolio of biotech companies with drugs in Phase II and Phase III of U.S. Food and Drug Administration (FDA) clinical trials, and limits itself to US-listed firms with market caps between USD 200 million and USD 5 billion. SBIO also screens for sustainability, meaning constituent firms have enough cash on hand to last two years. Given the low historical success rates in clinical trials, the fund is a high-risk, high-reward bet on a small subset of biotech companies. The Underlying Index undergoes semi-annual reconstitution and quarterly rebalance subject to certain caps. The largest stock is capped at 4.5%, and the excess weight is redistributed proportionately over the remainder of the Underlying Index. Prior to July 9, 2019 the fund's index was Poliwogg Medical Breakthroughs Index, which has the same strategies.